Literature DB >> 24267779

Impact and predictors of acute exacerbation of interstitial lung diseases after pulmonary resection for lung cancer.

Toshihiko Sato1, Satoshi Teramukai2, Haruhiko Kondo3, Atsushi Watanabe4, Masahito Ebina5, Kazuma Kishi6, Yoshitaka Fujii7, Tetsuya Mitsudomi8, Masahiro Yoshimura9, Tomohiro Maniwa10, Kenji Suzuki11, Kazuhiko Kataoka12, Yukihiko Sugiyama13, Takashi Kondo14, Hiroshi Date15.   

Abstract

OBJECTIVE: The study objective was to examine the incidence, risk factors, and mortality rate of acute exacerbation of interstitial lung diseases in patients with lung cancer undergoing pulmonary resection in a large-scale multi-institutional cohort.
METHODS: We retrospectively analyzed 1763 patients with non-small cell lung cancer who had undergone pulmonary resection and presented with a clinical diagnosis of interstitial lung diseases between January 2000 and December 2009 at 61 hospitals in Japan. The incidence and outcomes of acute exacerbation within 30 days from the operation were investigated. Univariate and multivariate logistic regression analyses were used to identify independent risk factors of acute exacerbation.
RESULTS: Acute exacerbation occurred in 164 patients (9.3%; 95% confidence interval, 8.0-10.8), with a mortality rate of 43.9%, and was the top cause of 30-day mortality (71.7%). The following 7 independent risk factors of acute exacerbation were identified: surgical procedures, male sex, history of exacerbation, preoperative steroid use, serum sialylated carbohydrate antigen KL-6 levels, usual interstitial pneumonia appearance on computed tomography scan, and reduced percent predicted vital capacity. Surgical procedures showed the strongest association with acute exacerbation (using wedge resection as the reference, lobectomy or segmentectomy: odds ratio, 3.83; 95% confidence interval, 1.94-7.57; bi-lobectomy or pneumonectomy: odds ratio, 5.70; 95% confidence interval, 2.38-13.7; P < .001). The effect of perioperative prophylactics, such as steroids and sivelestat, was not confirmed in this study.
CONCLUSIONS: Pulmonary resection for patients with lung cancer with interstitial lung diseases may provoke acute exacerbation at a substantially high rate and has high associated mortality. Surgical procedures that proved to be a risk factor for acute exacerbation should be chosen cautiously for these high-risk patients.
Copyright © 2014 The American Association for Thoracic Surgery. Published by Mosby, Inc. All rights reserved.

Entities:  

Mesh:

Year:  2013        PMID: 24267779     DOI: 10.1016/j.jtcvs.2013.09.050

Source DB:  PubMed          Journal:  J Thorac Cardiovasc Surg        ISSN: 0022-5223            Impact factor:   5.209


  75 in total

1.  Outcomes of lung cancer resection for patients with combined pulmonary fibrosis and emphysema.

Authors:  Mariko Fukui; Kenji Suzuki; Takeshi Matsunaga; Shiaki Oh; Kazuya Takamochi
Journal:  Surg Today       Date:  2015-08-15       Impact factor: 2.549

2.  Interstitial lung abnormalities in treatment-naïve advanced non-small-cell lung cancer patients are associated with shorter survival.

Authors:  Mizuki Nishino; Stephanie Cardarella; Suzanne E Dahlberg; Tetsuro Araki; Christine Lydon; David M Jackman; Michael S Rabin; Hiroto Hatabu; Bruce E Johnson
Journal:  Eur J Radiol       Date:  2015-02-07       Impact factor: 3.528

3.  Acute exacerbation of idiopathic interstitial pneumonia after nonpulmonary surgery under general anesthesia: a retrospective study.

Authors:  Kenta Furuya; Susumu Sakamoto; Yujiro Takai; Nobukazu Sato; Keiko Matsumoto; Sakae Homma
Journal:  Sarcoidosis Vasc Diffuse Lung Dis       Date:  2017-04-28       Impact factor: 0.670

4.  Postoperative pyothorax a risk factor for acute exacerbation of idiopathic interstitial pneumonia following lung cancer resection.

Authors:  Satoru Kobayashi; Yoko Karube; Morimichi Nishihira; Takashi Inoue; Osamu Araki; Sumiko Maeda; Tetsu Sado; Yuji Matsumura; Masayuki Chida
Journal:  Gen Thorac Cardiovasc Surg       Date:  2016-06-08

Review 5.  Lung cancer and interstitial lung disease: a literature review.

Authors:  Jean-Marc Naccache; Quentin Gibiot; Isabelle Monnet; Martine Antoine; Marie Wislez; Christos Chouaid; Jacques Cadranel
Journal:  J Thorac Dis       Date:  2018-06       Impact factor: 2.895

6.  Perioperative pirfenidone treatment for lung cancer patients with idiopathic pulmonary fibrosis.

Authors:  Masatoshi Kanayama; Masataka Mori; Hiroki Matsumiya; Akihiro Taira; Shinji Shinohara; Taiji Kuwata; Naoko Imanishi; Kazue Yoneda; Koji Kuroda; Fumihiro Tanaka
Journal:  Surg Today       Date:  2019-11-26       Impact factor: 2.549

7.  Clinical features and outcomes of patients with lung cancer as well as combined pulmonary fibrosis and emphysema.

Authors:  Hajime Otsuka; Keishi Sugino; Yoshinobu Hata; Takashi Makino; Satoshi Koezuka; Kazutoshi Isobe; Naobumi Tochigi; Kazutoshi Shibuya; Sakae Homma; Akira Iyoda
Journal:  Mol Clin Oncol       Date:  2016-07-08

8.  What factors determine the survival of patients with an acute exacerbation of interstitial lung disease after lung cancer resection?

Authors:  Masahiro Miyajima; Atsushi Watanabe; Toshihiko Sato; Satoshi Teramukai; Masahito Ebina; Kazuma Kishi; Yukihiko Sugiyama; Haruhiko Kondo; Satoru Kobayashi; Yutaka Takahashi; Hiroyuki Ito; Ryoji Yamamoto; Shigeki Sawada; Hideki Fujimori; Kazunori Okabe; Jun Arikura; Yasushi Shintani; Hiroshige Nakamura; Shinichi Toyooka; Tohru Hasumi; Takehiro Watanabe; Yoshinobu Hata; Hisashi Iwata; Minoru Aoki; Kazuhito Funai; Shuhei Inoue; Osamu Kawashima; Tomohiko Iida; Hiroshi Date
Journal:  Surg Today       Date:  2017-11-09       Impact factor: 2.549

9.  Prognostic impact of underlying lung disease in pulmonary wedge resection for lung cancer.

Authors:  Takeshi Kawaguchi; Noriyoshi Sawabata; Sachiko Miura; Norikazu Kawai; Motoaki Yasukawa; Takashi Tojo; Shigeki Taniguchi
Journal:  Int J Clin Oncol       Date:  2018-11-15       Impact factor: 3.402

10.  Life-threatening complications after pulmonary resection for lung cancer in patients on chronic hemodialysis.

Authors:  Kenji Tomizawa; Katsuaki Sato; Shuta Ohara; Toshio Fujino; Takamasa Koga; Masaya Nishino; Yoshihisa Kobayashi; Masato Chiba; Masaki Shimoji; Kenichi Suda; Toshiki Takemoto; Tetsuya Mitsudomi
Journal:  Surg Today       Date:  2019-01-31       Impact factor: 2.549

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.